AR078882A1 - Conjugados glucosilados de molecula de motivo repetido - Google Patents

Conjugados glucosilados de molecula de motivo repetido

Info

Publication number
AR078882A1
AR078882A1 ARP100104063A ARP100104063A AR078882A1 AR 078882 A1 AR078882 A1 AR 078882A1 AR P100104063 A ARP100104063 A AR P100104063A AR P100104063 A ARP100104063 A AR P100104063A AR 078882 A1 AR078882 A1 AR 078882A1
Authority
AR
Argentina
Prior art keywords
repeated
conjugates
independently
glucosyled
molecula
Prior art date
Application number
ARP100104063A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR078882A1 publication Critical patent/AR078882A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente memoria se informa de un conjugado glucosilado de molécula de motivo repetido de la formula siguiente: (molécula de motivo repetido - línkern)m - pareja de conjugacion - (línker0 - molécula de motivo repetido)p, en la que n y o son, independientemente uno de otro e independientemente para cada valor de m y p, valores enteros de 0 o 1, y m y p son, independientemente uno de otro, valores enteros de 0 o 1 o 2 o 3 o 4 o 5 o 6 o 7, y en la que el conjugado de molécula de motivo repetido comprende por lo menos un oligosacárido unido a un sitio de glucosilacion. También se informa de ácidos nucleicos codificantes y de un método para la produccion de dichos conjugados de motivo repetido en células de mamífero.
ARP100104063A 2009-11-05 2010-11-03 Conjugados glucosilados de molecula de motivo repetido AR078882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09013887 2009-11-05

Publications (1)

Publication Number Publication Date
AR078882A1 true AR078882A1 (es) 2011-12-07

Family

ID=41821255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104063A AR078882A1 (es) 2009-11-05 2010-11-03 Conjugados glucosilados de molecula de motivo repetido

Country Status (15)

Country Link
US (1) US10280214B2 (es)
EP (1) EP2496603B1 (es)
JP (1) JP5735972B2 (es)
KR (1) KR101528392B1 (es)
CN (2) CN102597000A (es)
AR (1) AR078882A1 (es)
BR (1) BR112012010591A2 (es)
CA (1) CA2778203C (es)
IL (2) IL218911A0 (es)
MX (1) MX2012004680A (es)
MY (1) MY162320A (es)
NZ (1) NZ599081A (es)
TW (1) TW201120210A (es)
WO (1) WO2011054519A1 (es)
ZA (1) ZA201202807B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
EP2818480B1 (en) * 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
CN104508129A (zh) * 2012-06-28 2015-04-08 分子伴侣公司 设计的与血小板衍生生长因子结合的锚蛋白重复序列蛋白
WO2014060365A1 (en) * 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) * 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
RU2015140915A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
ES2821940T3 (es) * 2014-05-19 2021-04-28 Hoffmann La Roche Procedimiento para la producción de polipéptidos
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2020263943A1 (en) * 2019-06-24 2020-12-30 University Of Georgia Research Foundation, Inc. Dual drug antibody-drug conjugates

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
GB9222931D0 (en) 1992-11-02 1992-12-16 Sandoz Ltd Organic compounds
DE69232604T2 (de) * 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
US5512473A (en) 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2000008177A2 (en) 1998-08-04 2000-02-17 Immunex Corporation Death associated kinase containing ankyrin repeats (dakar)
WO2002018648A2 (en) 2000-08-25 2002-03-07 President And Fellows Of Harvard College Analysis of binding interactions
CA2421447C (en) * 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US20030143612A1 (en) 2001-07-18 2003-07-31 Pointilliste, Inc. Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1403282A1 (en) 2002-09-26 2004-03-31 Cellzome Ag Protein complexes of the Tumor necrosis factor-alpha (TNF-alpha) signalling pathway
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
EP1641826A2 (en) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005076902A2 (en) 2004-02-06 2005-08-25 Mccormick & Company, Inc. Flavoring matrix compositions, methods for preparing the same, methods for using the same, and food prepared from the same
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
CN101056646A (zh) 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
JP2008520207A (ja) 2004-11-16 2008-06-19 アヴィディア リサーチ インスティテュート タンパク質骨格およびその使用
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP1941043B1 (en) * 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
KR20080082629A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 간세포 성장인자 인트론 융합 단백질
US20100015661A1 (en) 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US8106166B2 (en) 2007-03-16 2012-01-31 Stowers Institute For Medical Research Antibodies that bind specifically to phosphorylated β-catenin
WO2008135237A1 (en) 2007-05-03 2008-11-13 Medizinische Universität Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
CA2699916A1 (en) * 2007-09-18 2009-08-06 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
CL2008003561A1 (es) 2007-11-30 2010-02-05 Glaxo Group Ltd Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates

Also Published As

Publication number Publication date
JP5735972B2 (ja) 2015-06-17
BR112012010591A2 (pt) 2016-11-29
IL259430A (en) 2018-07-31
AU2010314450A1 (en) 2012-04-26
EP2496603B1 (en) 2018-07-18
CA2778203C (en) 2018-09-11
CN106977598A (zh) 2017-07-25
ZA201202807B (en) 2018-11-28
WO2011054519A1 (en) 2011-05-12
IL218911A0 (en) 2012-06-28
KR20120089487A (ko) 2012-08-10
CN102597000A (zh) 2012-07-18
TW201120210A (en) 2011-06-16
IL259430B (en) 2019-01-31
RU2012122869A (ru) 2013-12-10
JP2013509868A (ja) 2013-03-21
US10280214B2 (en) 2019-05-07
KR101528392B1 (ko) 2015-06-11
US20120309940A1 (en) 2012-12-06
NZ599081A (en) 2014-05-30
MX2012004680A (es) 2012-06-14
MY162320A (en) 2017-05-31
EP2496603A1 (en) 2012-09-12
CA2778203A1 (en) 2011-05-12
US20190135901A9 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
AR078882A1 (es) Conjugados glucosilados de molecula de motivo repetido
AR109500A2 (es) Composiciones de tigeciclina y métodos de preparación
BR112012033108A2 (pt) módulo solar
BR112012027792A2 (pt) flange plástico reforçado com fibra modular, viga compósita estrutural, métodos para formar um flange plástico reforçado com fibra modular, e para formar uma viga compósita estrutural, e, kit de partes
BR122017021516B8 (pt) processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
NI200600240A (es) FORMA CRISTALINA Delta-d CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN, Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
ECSP11011214A (es) Compuestos y método de uso
CU20120062A7 (es) Derivados de glicósido y usos de los mismos
EA201190242A1 (ru) Липидные композиции
BRPI0910388A2 (pt) agentes terapêutico antivirais.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
NO20091025L (no) Arylsulfonamider med analgesisk virkning
BR0316470A (pt) Derivados de 3-amino-piperadina e métodos de preparação
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
BRPI0812766B8 (pt) Processo para preparação de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
ECSP10010058A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
ECSP10010091A (es) Proceso para producir 2-desoxi-5-azacitidina (decitabina)
BR112012013119A2 (pt) derivados de 1-amino-piperidina-pirrolidina-diona espirocondensada com atividade pesticida.
BR112014004417A2 (pt) processo de isomerização da glicose em frutose
BRPI0517390B8 (pt) processo para a preparação de derivados de [1,4,5]-oxadiazepam

Legal Events

Date Code Title Description
FC Refusal